
Glarikot 750mg Tablet ER
Marketer
Glarizonto Pharma
Salt Composition
Valproic Acid (750mg)
Overview Glarikot 750mg Tablet ER
Epilepsy, bipolar disorder, and migraine prevention are addressed by the extended-release Glarikot 750mg tablet. Its mechanism involves neural calming, promoting brain relaxation. Administer this medication as directed, with or without food, consistently at the same time daily. Missed doses should be taken immediately upon recollection. Complete the prescribed course, even with symptom improvement; abrupt cessation may trigger increased seizure activity. Consult your physician before discontinuing. Commonly reported side effects encompass headache, blurred vision, appetite suppression, nausea, vomiting, alopecia, diarrhea, somnolence, and dizziness. Refrain from operating machinery or engaging in tasks requiring concentration until the drug's effects are understood. Weight gain is possible; maintain a healthy diet and exercise routine to mitigate this. Report persistent or bothersome side effects to your doctor.
Uses of Glarikot 750mg Tablet ER
Seizure Control | Migraine Prophylaxis | Management of Bipolar Disorder
Major Benefits of Glarikot 750mg Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the entire tablet; avoid chewing, crushing, or breaking it. Glarikot 750mg Extended-Release tablets should be administered with a meal.
Common Side effects of Glarikot 750mg Tablet ER:
- Headache
- Dizziness
- Blurred vision
- Loss of appetite
- Nausea
- Vomiting
- Sleepiness
- Hair loss
- Weight gain
- Tremors
- Double vision
- Diarrhea
- Impaired coordination
- Increased appetite
- Weakness
- Stomach pain
How to use Glarikot 750mg Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 750mg Glarikot Extended-Release tablet whole; do not break, crush, or chew it. Administer this medication with food.
How Glarikot 750mg Tablet ER works:
Epileptic seizures are managed by the extended-release Glarikot 750mg tablet, an anticonvulsant that reduces hyperactivity within the brain's neuronal network.
SAFETY ADVICE
AlcoholUNSAFE
Combining Glarikot 750mg Extended-Release Tablets with alcohol is hazardous.
PregnancyCONSULT YOUR DOCTOR
Extended-release Glarikot 750mg tablets pose a confirmed risk to the fetus and should not be taken during pregnancy. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential advantages outweigh the known dangers. Physician consultation is essential.
Breast feedingSAFE IF PRESCRIBED
Extended-release Glarikot 750mg tablets are considered safe for use while breastfeeding. Research in humans indicates minimal drug transfer to breast milk, posing no discernible risk to the infant.
DrivingUNSAFE
Extended-release Glarikot 750mg tablets can cause drowsiness, blurred vision, and dizziness. Driving should be avoided if these side effects are experienced.
KidneyCAUTION
Extended-release Glarikot 750mg tablets require careful administration for individuals with impaired kidney function. Dosage modification of Glarikot 750mg ER tablets may be necessary. A physician's consultation is recommended. Kidney disease should be disclosed to your doctor.
LiverUNSAFE
Extended-release Glarikot 750mg tablets are likely unsuitable for individuals with hepatic impairment and should be omitted. Medical advice is recommended. Patients exhibiting severe or active liver disease should not use Glarikot 750mg extended-release tablets.
What if you forget to take Glarikot 750mg Tablet ER :
Should you forget a Glarikot 750mg Extended-Release Tablet, take it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed one and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glarikot 750mg Tablet ER
| Label | Value |
|---|---|
| Chemical Classification | Valproate |
| Developing Habits | No. |
| Treatment Category | Neuroscience of the Central Nervous System |
| Action Class | Antiepileptic drugs targeting sodium channels |
